Ethical Issues in Providing Payment for HIV and Drug Use Research

BRANDON BROWN
UNIVERSITY OF CALIFORNIA RIVERSIDE SCHOOL OF MEDICINE CENTER FOR HEALTHY COMMUNITIES
Objectives

Case study
Personal interest
How payment is used in research
Why should we care
Potential solutions
Case Study

“We are conducting a HIV cure study among positive injection drug users. You may not directly benefit from participation in this study. For more information please contact Brandon Brown at 951-990-9899”
We are conducting a 1 HIV cure study among positive injection drug users. You may not directly benefit from participation in this study. 2

<table>
<thead>
<tr>
<th>Including text</th>
<th>Proposed amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No additional text</strong></td>
<td>$0</td>
</tr>
<tr>
<td><strong>1 biomedical, multiple visit, 2 year</strong></td>
<td>$5,000</td>
</tr>
<tr>
<td><strong>1 &amp; 2 biomedical, multiple visit, 2 year</strong></td>
<td>$50,000</td>
</tr>
<tr>
<td>In order to participate, you must halt the use of your antiretroviral treatment, which may make you sick or infectious</td>
<td></td>
</tr>
</tbody>
</table>
Case study - what are the issues?

There is diversity in decision making

- Wording + details
- Altruism
- Experience in research
- Perceptions
  - Payment & safety
Would knowing what has been provided in past studies help your decision?

Is there something other than monetary payment that should be considered?

If your role changes, does your suggested payment change?

◦ Imagine you are:
  ◦ the participant
  ◦ the IRB
  ◦ the PI of the study
  ◦ the study sponsor (funder)
Main concern

What is the main question or concern with payment from an ethical and regulatory perspective?
Regulatory Parameters

The regulations instruct IRBs to minimize the possibility of coercion and undue influence during informed consent.

- Neither the Common Rule nor FDA regulations explicitly connect payment with ‘coercion’ or ‘undue influence’ or discuss payment at all
- But payment is discussed in an Office of Human Research Protections (OHRP) ‘FAQ’ and an FDA Information Sheet …
‘When does compensating subjects undermine informed consent or parental permission?’

◦ “Paying research participants in exchange for their participation is a common and, in general, acceptable practice.”

“IRBs should be cautious that payments are not so high that they create an ‘undue influence’ or offer undue inducement to participate in research.”
The Regulatory Challenge…

So, according to regulatory guidance…

◦ Payment is generally acceptable …

◦ So long as it does not ‘unduly influence’ or ‘coerce’ individuals to participate in research.
‘Coercion’ and ‘Undue Influence’

OHRP’s definitions…

◦ “Coercion occurs when an overt or implicit threat of harm is intentionally presented by one person to another in order to obtain compliance.”

◦ “Undue influence, by contrast, often occurs through an offer of an excessive or inappropriate reward or other overture in order to obtain compliance.”
What Is ‘Undue’ Influence?

OHRP: undue influence occurs when payment **distorts** an individual’s decision to participate in research

- Payment as undue influence = “**compromise a prospective subject’s examination and evaluation of the risks or affect the voluntariness of his or her choices.**”

- Empirical question; some data that payment **increases** perception of risks and caution among subjects
If the IRB Independently Determines the Risks to Be Reasonable...

For most people in the study population, participating will not be a bad or unreasonably risky choice.
  ◦ If it were, something has gone wrong with risk-benefit analysis.

Does not eliminate risks of payment entirely but should significantly diminish concerns.
  ◦ Some people may have idiosyncratic situations or values that IRB cannot be expected to anticipate.
Three Main Payment Categories

Reimbursement
- Payment for out of pocket expenses incurred as part of research participation

Compensation for time/burdens
- Subjects paid for time and undertaking burdens of research

Recruitment incentives
- Offered to improve recruitment and participation rates
Incentives are everywhere
Sometimes acceptable, sometimes not
Sometimes you pay, sometimes get paid*
‘Real life’ different than research
  ◦ In research, usually talk about participant getting something
When some people think of incentives ($$$),
## Initial Interest in incentives

Incentives provided to similar participants in three studies of infectious diseases in Lima, Peru.

<table>
<thead>
<tr>
<th></th>
<th>Study 1</th>
<th>Study 2</th>
<th>Study 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Money</td>
<td>None</td>
<td>U.S.$7.00</td>
<td>None</td>
</tr>
<tr>
<td>Gifts</td>
<td>Watch, makeup, purse, wallet</td>
<td>Annual birthday present, watch, perfume, makeup purse, wallet, hair dryer, lunches</td>
<td>Nothing</td>
</tr>
<tr>
<td>Health services</td>
<td>Birth control, genital wart removal, condoms and lubricants, and HIV testing</td>
<td>Birth control, genital wart removal, condoms and lubricants, STD treatment and medical attention for participants and family, annual breast exam and Pap smear, and HIV testing</td>
<td>Genital wart removal, HIV testing, annual Pap smear, and syndromic treatment</td>
</tr>
</tbody>
</table>

Retrospective analysis of participation in clinical trial

<table>
<thead>
<tr>
<th>Measure</th>
<th>Agreed</th>
<th>Disagreed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study well described in consent</td>
<td>14</td>
<td>2</td>
</tr>
<tr>
<td>Participation is voluntary</td>
<td>16</td>
<td>0</td>
</tr>
<tr>
<td>Felt they could withdraw at anytime without loss</td>
<td>13</td>
<td>3</td>
</tr>
<tr>
<td>Enjoyed participating in the study</td>
<td>15</td>
<td>1</td>
</tr>
<tr>
<td>Primary reason for participating was CC screening</td>
<td>16</td>
<td>0</td>
</tr>
<tr>
<td>Study should have paid us</td>
<td>3</td>
<td>13</td>
</tr>
</tbody>
</table>
Incentives History: Tuskegee Experiments

1932-72, Tuskegee, Alabama

Public health doctors (NIH) followed African American men with syphilis
  ◦ Goal of learning about the disease history

Did not tell participants they had syphilis

When Penicillin became available (1947), did not treat
  ◦ “It was important that they were untreated, and it would be undesirable to go ahead and use large amounts of penicillin to treat the disease, because you’d interfere with the study”

For participants: free medical care, meals, and burial insurance

For investigators…
Willowbrook state school Experiments

Children with intellectual disability-NY
1956-1972, children intentionally infected with hepatitis
- Study sponsored by US army
- Goal to develop vaccine

Given facility conditions, PI argued children would be exposed naturally
Issues
- Long waiting lists for children to be admitted to the school
- Parents consenting to participate in the study allowed to enroll their disabled children
- Only school of its kind at the time in the area
Incentives in research

money, snacks, health care, gifts
means of encouraging participation
  ◦ Skewed sample selection?
  ◦ Marginalized-risk*

"High-Pay" of the Day®

A $17,000 Sleep Study!
Wow! Need some easy cash? Well, check out this High-Pay sleep study. Yes, this program will pay you $17,000 to participate in this unique sleep study being conducted by a government sponsored agency. One of many "High Pay-Get Paid" opportunities listed with NRG.
Sign up and check it out.

Latest Opportunities

- $6,875.00
  Males Between 18-45 years old
  Generally healthy
  Wiling to provide up to 8 sperm samples.
- $3,820.00
  Do you have Hepatitis C?
  Ages 18-60
  Men & Women Needed!
  Includes time and travel compensation
- $1,155.00
  Healthy Men & Women Needed!
  Ages 18-55
  Profile: Cocaine & Opiate Abuse
Planning a new HS research study*

What are appropriate incentives?
- Who should be making the decision?
- How should this decision be made?*
- Decision can be hard
  - Transparency-reference data

We have few incentive data

Currently no public record of incentives
  ◦ Not easily searchable-IRB

No guidance on what types/amounts to provide*

No working definition of excessive incentives
  ◦ Undue inducement*

The Belmont Report

Ethical Principles and Guidelines for the Protection of Human Subjects of Research

The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research

April 18, 1979
Why should we care about incentives?

Impact research outcomes
- Enthusiasm to join, not adhere
  - Examples of this in HIV research

Professional research subjects
- Fabricate/conceal-symptoms/behaviors*

Research studies “monetizing” acts-HIV testing*

http://www.hivequal.org/hiv-equal-online/prep-works-for-transgender-women-but-only-if-they-use-it
Incentives in the literature

Few publications report incentives/payment

Dickert et al 2002 ‘Paying research subjects’
- 37.5% of orgs had policies on payment
- 20% of groups knew what % of their studies paid

Grady et al. 2005 ‘Analysis of US Practices’
- 467 clinical studies with range of payment $5-$2000
- Unexplained variation
Incentive Decision Making

Perfect world
- study team engages potential participants beforehand*
- Review of previous studies, contact PIs
  - Lengthy process

Real world
- Make quick decisions, deadlines
- depends on budget, beliefs, standards

IRBs review incentive amounts proposed by investigators
- Approve or deny
- May rely on investigator to do ‘due diligence’
Ex: How payments are evaluated (IRB)

The purpose of this worksheet is to provide support for the convened IRB or Designated Reviewers when evaluating payments to subjects or their legally authorized representatives. This worksheet is to be used. It does not have to be completed or retained.

<table>
<thead>
<tr>
<th>Requirements for Payments (Check if “Yes”. All must be checked)</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ All payments are described in the protocol including:</td>
</tr>
<tr>
<td>☐ Amount</td>
</tr>
<tr>
<td>☐ Method</td>
</tr>
<tr>
<td>☐ Timing of disbursement</td>
</tr>
<tr>
<td>☐ Credit for payment accrues as the study progresses.</td>
</tr>
<tr>
<td>☐ Payment is not contingent upon completing the entire study.</td>
</tr>
<tr>
<td>☐ The amount of payment and the proposed method and timing of disbursement is neither coercive nor presented undue influence.</td>
</tr>
<tr>
<td>☐ Any amount paid as a bonus for completion is reasonable and not so large as to unduly induce subjects to stay in the study when they would otherwise have withdrawn.</td>
</tr>
<tr>
<td>☐ All information concerning payment, including the amount and schedule of payments, is in the informed consent document.</td>
</tr>
<tr>
<td>☐ Compensation does not include a coupon good for a discount on the purchase price of the product once it has been approved.</td>
</tr>
<tr>
<td>☐ For studies that compensate subjects, the following statement is included in the consent form: ‘According to the rules of the Internal Revenue Service (IRS), payments that are made to you as a result of your participation in a study may be considered taxable income.’</td>
</tr>
</tbody>
</table>
Determining appropriate incentives

- Query of incentive amounts/types across studies
- Full reporting DNE

ClinicalTrials.gov
A service of the U.S. National Institutes of Health

The Role of Genital Warts in HIV Acquisition in Peru (VIVA)

This study has been completed.

Sponsor:
University of California, Los Angeles

Collaborators:
Espacio Comun
Universidad Peruana Cayetano Heredia

Information provided by (Responsible Party):
Brandon Brown, University of California, Los Angeles

ClinicalTrials.gov Identifier:
NCT01387412

First received: June 30, 2011
Last updated: November 30, 2015
Last verified: November 2015
History of Changes
First Step-Get Input from stakeholders

Query Investigators and IRB members
  ◦ How they think about incentives

Que Participants
  ◦ Fair and unfair payment/incentives
  ◦ Do incentives make a difference
Second step-Consensus

Decide on relevant parameters related to incentives*

<table>
<thead>
<tr>
<th>Context</th>
<th>Research</th>
<th>Incentives</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location</td>
<td>Condition under study</td>
<td>Type (money, gifts, services)</td>
</tr>
<tr>
<td>Average income</td>
<td>Study population (age, sex, race)</td>
<td>Amount (set, varied)</td>
</tr>
<tr>
<td>Morbidity/mortality</td>
<td>Risks and burdens</td>
<td>Frequency</td>
</tr>
<tr>
<td>Health services available</td>
<td>Benefits (direct, indirect)</td>
<td>Post-trial access</td>
</tr>
<tr>
<td>Health literacy</td>
<td>Study procedures (time, visits)</td>
<td>Reimbursement</td>
</tr>
</tbody>
</table>

*Note: The asterisk indicates a special emphasis on the importance of considering the context, research, and incentives in decision-making.
Third Step-Delphi Panel with vignettes

Judge 3 values per vignette
  ◦ Appropriate, too much, too little
  ◦ Ex: values are $100, $500, $2000
Sample Vignette (variables from Table):

You have been HIV positive for X years. For the past year your health has been Y. You have the opportunity to participate in a phase II study of HIV cure including an intervention which has proved safe in phase I trials but with unknown efficacy, and with a Z risk of adverse health effects. In order to participate in the trial, you must halt your antiretroviral medications for the duration of the study period AA. Your income is BB. Would $500 be an appropriate incentive to participate?

<table>
<thead>
<tr>
<th>Years w/HIV</th>
<th>Health Status</th>
<th>Study Risk</th>
<th>Study Time in Years</th>
<th>Income</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>Y</td>
<td>Z</td>
<td>AA</td>
<td>BB</td>
</tr>
<tr>
<td>1</td>
<td>Poor</td>
<td>High</td>
<td>1</td>
<td>Low</td>
</tr>
<tr>
<td>5</td>
<td>Okay</td>
<td>Medium</td>
<td>2</td>
<td>Medium</td>
</tr>
<tr>
<td>20</td>
<td>Excellent</td>
<td>Low</td>
<td>10</td>
<td>High</td>
</tr>
</tbody>
</table>
Last step

Figure 5: Incentive decision making schematic

Input: Study/Context Data

Output: Incentive

Study Parameters

[Suggested Incentive]

Incentive Range

Too Little | Gray Area

Too Much | Gray Area
Potential benefits of the results

Aid incentive decision making in HS research
  ◦ Report results of tool

Empower participants/community leaders
Additional benefits

Use incentive tool/database to…..
  ◦ analyze impact of incentives on recruitment/retention*
  ◦ Discuss what incentives are appropriate*
What about the risks

Transparency means access
  • Participants say no

Underfunded studies not allowed to proceed
If you don’t buy my arguments

- Its OK!
- HPTN
- PCORI
- IRB
- Harvard Payment working group
  - Making guidance document
  - NIH, OHRP, IRBs, CDC, Universities, pharma
Hypothesis-‘going rate’ of incentives in research

Market forces for going rate
  ◦ How much to pay someone for a FG

Ex outside research
  ◦ short trip from Los Angeles to New York City
  ◦ Oversold flight
    ◦ Offers for taking later flight-incremental incentives
      ◦ $200+flight
      ◦ $250+dinner voucher+flight
      ◦ $300+dinner voucher+flight
Next steps

Interviews with participants for a hypothetical HIV cure study
  ◦ Varying payment amount, asking about participation, asking about risk
  ◦ Answer Q: ‘Does high payment suspend people’s ability to see risk or to act on it’

PCORI methods grant
  ◦ Fingers crossed
Questions?

“We found the donut to be more of an incentive for him.”